In­cyte keeps rolling on top­i­cal cream for JAK in­hibitor, pass­ing two PhI­II tests in vi­tili­go

As In­cyte pre­pares to po­ten­tial­ly hit the mar­ket with a top­i­cal for­mu­la­tion of its cash cow rux­oli­tinib in atopic der­mati­tis, the Wilm­ing­ton, DE-based com­pa­ny is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER